Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves Kindred treatment for problem weight loss in cats

Kindred Biosciences Inc. received the first U.S. approval for a treatment for unintended weight loss in cats.

Read More »

Drinking problems tied to higher risk of early dementia

Heavy drinkers may be more likely than other adults to develop dementia, especially in middle age, a French study suggests.

Read More »

Sound therapy may train brain to ignore tinnitus

A sound-emitting device worn in the ear during sleep may train the brain to ignore an annoying chronic ringing in the ears, a new study suggests.

Read More »

Troubled Otonomy Cuts Jobs

Otonomy, which develops innovative therapeutics for diseases and disorders of the ear, is initiating more job cuts as well as planning to divest one of its assets.

Read More »

Auris Abandons Hearing-Loss Drug After Phase III Flop, Stock Sinks

Auris Medical Holding’s HEALOS Phase III clinical trial of AM-111 for acute inner ear hearing loss failed to meet its primary endpoint.

Read More »

Otonomy Lead Drug Succeeds in Late-Stage Study

Otonomy announced the success of its AVERTS-2 Phase III clinical trial of Otividex in patients with Meniere’s disease.

Read More »

Otonomy Slashes Staff After Failed Phase III Study

Otonomy is cutting jobs and slashing operations in order to stay in business.

Read More »

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc. suspended developing its drug for Meniere’s disease, a chronic disorder of the inner ear, after it failed a late-stage trial.

Read More »

FDA approves Medicines Co.’s urinary tract infection drug

The U.S. Food and Drug Administration approved Medicines Co.’s antibacterial drug for patients with complicated urinary tract infections (cUTI).

Read More »

Vision loss associated with cognitive decline, dementia

Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom